Actively Recruiting

Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
NCT06322238

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

Led by Mayo Clinic · Updated on 2025-10-14

66

Participants Needed

1

Research Sites

121 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').

CONDITIONS

Official Title

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is 18 years or older
  • Receiving a first prescription for a drug included in the study's list with no prescription for that drug in the past 12 months
  • Willing and able to participate and be followed for 48 weeks
  • Able to provide a saliva sample
  • Has signed informed consent
  • Has computer access demonstrated by active use of a patient portal or email
Not Eligible

You will not qualify if you...

  • Previous pharmacogenomic testing including genes in the study panel (investigational arm only)
  • Pregnant or lactating
  • Life expectancy less than three months or receiving hospice care
  • Planned treatment with the index drug for less than seven consecutive days
  • Currently an inpatient
  • Unable to provide consent
  • Unwilling to participate
  • No permanent address
  • No current primary care provider
  • Deemed unsuitable by study coordinator and clinical team
  • Diagnosis of stage 4 or 5 chronic kidney disease or receiving dialysis
  • Advanced liver failure (Child-Pugh C) or liver cirrhosis
  • History of liver transplant or allogeneic hematopoietic stem cell transplant
  • Insufficient DNA sample requiring retesting

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic

Rochester, Minnesota, United States, 55902

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: | DecenTrialz